Genetic Technologies Stock Probability Of Bankruptcy

GENE Stock  USD 2.39  0.02  0.84%   
Genetic Technologies' odds of distress is over 60% at the present time. It has an above-average probability of going through some form of financial hardship in the next 2 years. Genetic Technologies' Probability of distress is determined by interpolating and adjusting Genetic Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the Genetic balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Genetic Technologies Piotroski F Score and Genetic Technologies Altman Z Score analysis.
For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.
  
The current year's Working Capital is expected to grow to about 11.8 M, whereas Market Cap is forecasted to decline to about 628.9 M.

Genetic Technologies Company probability of distress Analysis

Genetic Technologies' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Genetic Technologies Probability Of Bankruptcy

    
  Over 63%  
Most of Genetic Technologies' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genetic Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Genetic Technologies probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Genetic Technologies odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Genetic Technologies financial health.
Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.15)
Revenue Per Share
2.73
Quarterly Revenue Growth
(0.02)
Return On Assets
(0.53)
Return On Equity
(1.60)
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Genetic Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Genetic Technologies is extremely important. It helps to project a fair market value of Genetic Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Genetic Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Genetic Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Genetic Technologies' interrelated accounts and indicators.
0.98-0.86-0.330.380.070.920.390.48-0.19-0.06-0.260.3-0.390.50.150.780.810.710.41
0.98-0.91-0.270.26-0.130.940.330.4-0.14-0.18-0.330.18-0.360.470.060.80.760.710.33
-0.86-0.910.4-0.090.25-0.96-0.46-0.210.320.510.460.070.54-0.120.28-0.9-0.61-0.64-0.18
-0.33-0.270.4-0.66-0.3-0.43-0.91-0.510.760.20.54-0.470.690.2-0.11-0.59-0.23-0.03-0.61
0.380.26-0.09-0.660.630.30.590.8-0.330.48-0.290.93-0.390.350.740.320.40.060.86
0.07-0.130.25-0.30.63-0.090.310.41-0.250.60.320.59-0.180.130.46-0.150.24-0.010.41
0.920.94-0.96-0.430.3-0.090.490.42-0.25-0.34-0.490.14-0.550.28-0.040.930.720.690.39
0.390.33-0.46-0.910.590.310.490.47-0.68-0.23-0.50.42-0.65-0.190.090.580.280.050.65
0.480.4-0.21-0.510.80.410.420.470.010.31-0.420.79-0.170.560.740.420.550.290.88
-0.19-0.140.320.76-0.33-0.25-0.25-0.680.010.290.04-0.130.680.520.22-0.33-0.020.04-0.2
-0.06-0.180.510.20.480.6-0.34-0.230.310.290.330.650.210.510.74-0.5-0.01-0.270.24
-0.26-0.330.460.54-0.290.32-0.49-0.5-0.420.040.33-0.240.38-0.06-0.08-0.64-0.060.04-0.37
0.30.180.07-0.470.930.590.140.420.79-0.130.65-0.24-0.150.520.90.130.32-0.070.82
-0.39-0.360.540.69-0.39-0.18-0.55-0.65-0.170.680.210.38-0.150.220.18-0.54-0.15-0.09-0.27
0.50.47-0.120.20.350.130.28-0.190.560.520.51-0.060.520.220.630.170.630.460.38
0.150.060.28-0.110.740.46-0.040.090.740.220.74-0.080.90.180.63-0.10.25-0.080.73
0.780.8-0.9-0.590.32-0.150.930.580.42-0.33-0.5-0.640.13-0.540.17-0.10.670.650.41
0.810.76-0.61-0.230.40.240.720.280.55-0.02-0.01-0.060.32-0.150.630.250.670.910.51
0.710.71-0.64-0.030.06-0.010.690.050.290.04-0.270.04-0.07-0.090.46-0.080.650.910.2
0.410.33-0.18-0.610.860.410.390.650.88-0.20.24-0.370.82-0.270.380.730.410.510.2
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, Genetic Technologies has a Probability Of Bankruptcy of 63%. This is 45.53% higher than that of the Life Sciences Tools & Services sector and 54.26% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 58.17% lower than that of the firm.

Genetic Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genetic Technologies' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genetic Technologies could also be used in its relative valuation, which is a method of valuing Genetic Technologies by comparing valuation metrics of similar companies.
Genetic Technologies is currently under evaluation in probability of bankruptcy category among related companies.

Genetic Technologies Main Bankruptcy Drivers

201920202021202220232024 (projected)
Return On Assets(0.4)(0.31)(0.34)(0.79)(0.91)(0.96)
Asset Turnover6.31E-40.0052480.330.580.670.46
Gross Profit Margin(9.86)(24.5)(1.99)0.950.50.58
Net Debt(13.7M)(20.7M)(11.1M)(7.3M)(6.6M)(6.9M)
Total Current Liabilities1.4M1.4M3.8M3.3M3.0M2.0M
Non Current Liabilities Total1.2M33.3K558.9K381.6K343.5K400.6K
Total Assets15.6M23.0M20.8M14.9M13.4M14.4M
Total Current Assets15.2M22.2M14.7M10.5M12.1M11.7M
Total Cash From Operating Activities(5.7M)(6.6M)(6.6M)(9.9M)(8.9M)(8.5M)

Genetic Fundamentals

About Genetic Technologies Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Genetic Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genetic Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genetic Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Genetic Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Genetic Technologies' short interest history, or implied volatility extrapolated from Genetic Technologies options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Genetic Technologies is a strong investment it is important to analyze Genetic Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Genetic Technologies' future performance. For an informed investment choice regarding Genetic Stock, refer to the following important reports:
Check out Genetic Technologies Piotroski F Score and Genetic Technologies Altman Z Score analysis.
For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Genetic Stock analysis

When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Transaction History
View history of all your transactions and understand their impact on performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Bonds Directory
Find actively traded corporate debentures issued by US companies
Global Correlations
Find global opportunities by holding instruments from different markets
Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.15)
Revenue Per Share
2.73
Quarterly Revenue Growth
(0.02)
Return On Assets
(0.53)
Return On Equity
(1.60)
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.